Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL

PHASE3CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

November 30, 2017

Study Completion Date

November 30, 2017

Conditions
Opioid Use Disorder
Interventions
DRUG

Naltrexone

daily dosing

DRUG

Placebo

daily dosing

DRUG

Buprenorphine

daily dosing

Trial Locations (9)

10032

New York State Psychiatric Institute, New York

15213

Western Psychiatric Institute and Clinic of University of Pittsburgh Medical Center, Pittsburgh

19104

University of Pennsylvania Treatment Research Center, Philadelphia

27705

Duke University Medical Center, Durham

33308

Segal Institute for Clinical Research, Lauderhill

33334

Research Centers of America, LLC, Oakland Park

60190

Neuroscience Research Institute, Inc., Winfield

21205-1911

John Hopkins School of Medicine, Baltimore

08009

Hassman Research Institute, Berlin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Alkermes, Inc.

INDUSTRY

NCT02696434 - Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL | Biotech Hunter | Biotech Hunter